CRP and myocardial infarction: In the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), patients with recent myocardial infarction and elevated high sensitivity C-reactive protein were randomized between several doses of canakinumab (a monoclonal antibody against interleukin-1β) and a placebo.